Skip to main content
Swing Capital

Sakar Healthcare Ltd

NSE: SAKARPharma

Incorporated in 2004, Sakar Healthcare Ltd is in the business of manufacturing Research & Development of Pharmaceutical products[1]

₹780
52W: ₹306 — ₹788
PE 56.9 · Book ₹146 · +434% vs book
Market Cap₹1,735 Cr
Stock P/E56.9Price to Earnings
ROCE12.7%Return on Capital
ROE9.99%Return on Equity
Div. Yield0%Face Value ₹10

Strengths

  • +Company has reduced debt.
  • +Company is expected to give good quarter
  • +Company has delivered good profit growth of 23.1% CAGR over last 5 years
  • +Company's median sales growth is 18.0% of last 10 years

Weaknesses

  • −Stock is trading at 5.17 times its book value
  • −Though the company is reporting repeated profits, it is not paying out dividend
  • −Company has a low return on equity of 7.49% over last 3 years.
  • −Promoter holding has decreased over last 3 years: -7.86%

Shareholding Pattern

Promoters52.86%
FIIs12.94%
DIIs11.32%
Public22.87%
CategoryJun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters53.15%53.15%53.58%▲0.453.58%52.86%▼0.752.86%52.86%52.86%
FIIs13.52%13.42%▼0.113.58%▲0.213.61%▲0.013.41%▼0.213.31%▼0.113.05%▼0.312.94%▼0.1
DIIs10.62%10.62%10.88%▲0.310.97%▲0.111.25%▲0.311.43%▲0.211.36%▼0.111.32%▼0.0
Public22.71%22.8%▲0.121.96%▼0.821.85%▼0.122.48%▲0.622.41%▼0.122.73%▲0.322.87%▲0.1

Financial Statements

MetricDec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Sales37434143435053587071
Expenses28323031323540465245
Operating Profit9111112121613111926
OPM %24%25%26%27%27%31%24%20%26%37%
Net Profit232556551011
EPS ₹0.951.431.112.212.062.622.12.044.614.95

AI Insights

Revenue Trend

Mar 2026 revenue at ₹252Cr, up 41.6% YoY. OPM at 27%.

Debt Position

Borrowings at ₹55Cr. Debt-to-equity ratio: 0.18x. Healthy balance sheet.

Capex Cycle

CWIP at ₹4Cr (1% of fixed assets). Moderate ongoing capital expenditure.

Institutional Flow

DIIs: 11.32% (+11.32pp change). FIIs: 12.94% (-2.80pp change). Promoters hold 52.86%.

Margin & Efficiency

ROCE declining from 14% (Mar 2015) to 13% (Mar 2026). Working capital days: 45.

Valuation

PE 56.9x with 12.7% ROCE. Price is 434% above book value of ₹146. Dividend yield: 0%.

Recent Announcements